國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Hereditary tyrosinemiapathogenesis, ...

SpringerLink (Online service)

Hereditary tyrosinemiapathogenesis, screening and management /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Hereditary tyrosinemiaedited by Robert M. Tanguay.
其他題名:	pathogenesis, screening and management /
其他作者:	Tanguay, Robert M.
出版者:	Cham :Springer International Publishing :2017.
面頁冊數:	xv, 247 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer eBooks
標題:	TyrosinosisDiagnosis.
電子資源:	http://dx.doi.org/10.1007/978-3-319-55780-9
ISBN:	9783319557809$q(electronic bk.)

Hereditary tyrosinemiapathogenesis, screening and management /
Hereditary tyrosinemiapathogenesis, screening and management /[electronic resource] :edited by Robert M. Tanguay. - Cham :Springer International Publishing :2017. - xv, 247 p. :ill. (some col.), digital ;24 cm. - Advances in experimental medicine and biology,v.9590065-2598 ;. - Advances in experimental medicine and biology ;946..

Section I: Tyrosinemia Type 1: Heredity -- Section II:The Molecular Basis of HTI -- Section III: Pathology -- Section IV: Screening, Management and The Future.

Hereditary tyrosinemia type 1 (HT1), the most severe inborn error of the tyrosine degradation pathway, is due to a deficiency in fumarylacetoacetate hydrolase (FAH) The worldwide frequency of HT1 is one per 100,000 births, but some regions have a significantly higher incidence (1:1,800) The FAH defect results in the accumulation of toxic metabolites, mainly in the liver. If left untreated, HT1 is usually fatal before the age of two. HT1 patients develop several chronic complications including cirrhosis with a high risk of hepatocellular carcinoma (HCC) and neuropsychological impairment. Treatment comprises an inhibitor of the pathway, Nitisinone, a strict dietary treatment or liver transplantation. Early treatment is important to avoid HCC. The book includes the latest developments on the molecular basis of HT1, its pathology, screening and diagnosis and management of the disease written by leading scientists, geneticists, hepatologists and clinicians in the field.

ISBN: 9783319557809$q(electronic bk.)

Standard No.: 10.1007/978-3-319-55780-9doiSubjects--Topical Terms:

789113
Tyrosinosis
--Diagnosis.

LC Class. No.: RC632.T9

Dewey Class. No.: 616.399

Hereditary tyrosinemiapathogenesis, screening and management /
LDR:02192nmm a2200325 a 4500 001 520057
003 DE-He213
005 20170728153844.0
006 m d
007 cr nn 008maaau
008 180425s2017 gw s 0 eng d
020 $a 9783319557809$q(electronic bk.)
020 $a 9783319557793$q(paper)
024 7 $a 10.1007/978-3-319-55780-9 $2 doi
035 $a 978-3-319-55780-9
040 $a GP $c GP
041 0 $a eng
050 4 $a RC632.T9
072 7 $a PSBC $2 bicssc
072 7 $a SCI007000 $2 bisacsh
082 0 4 $a 616.399 $2 23
090 $a RC632.T9 $b H542 2017
245 0 0 $a Hereditary tyrosinemia $h [electronic resource] : $b pathogenesis, screening and management / $c edited by Robert M. Tanguay.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2017.
300 $a xv, 247 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.959
505 0 $a Section I: Tyrosinemia Type 1: Heredity -- Section II:The Molecular Basis of HTI -- Section III: Pathology -- Section IV: Screening, Management and The Future.
520 $a Hereditary tyrosinemia type 1 (HT1), the most severe inborn error of the tyrosine degradation pathway, is due to a deficiency in fumarylacetoacetate hydrolase (FAH) The worldwide frequency of HT1 is one per 100,000 births, but some regions have a significantly higher incidence (1:1,800) The FAH defect results in the accumulation of toxic metabolites, mainly in the liver. If left untreated, HT1 is usually fatal before the age of two. HT1 patients develop several chronic complications including cirrhosis with a high risk of hepatocellular carcinoma (HCC) and neuropsychological impairment. Treatment comprises an inhibitor of the pathway, Nitisinone, a strict dietary treatment or liver transplantation. Early treatment is important to avoid HCC. The book includes the latest developments on the molecular basis of HT1, its pathology, screening and diagnosis and management of the disease written by leading scientists, geneticists, hepatologists and clinicians in the field.
650 0 $a Tyrosinosis $x Diagnosis. $3 789113
650 0 $a Tyrosinosis $x Treatment. $3 789114
650 1 4 $a Life Sciences. $3 273679
650 2 4 $a Protein Science. $3 376428
700 1 $a Tanguay, Robert M. $3 726212
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v 946. $3 557559
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-55780-9
950 $a Biomedical and Life Sciences (Springer-11642)